Search Videos and More
Video
Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor
Dana-Farber's Antonia Giordano, MD, PhD shares new data on a novel CDK4-selective inhibitor in como with letrozole as 1st line treatment in HR+/HER2 Metastatic Breast Cancer.
Video
Jennifer Ligibel, MD Discusses Weigh Loss Intervention
Dana-Farber's Jennifer Ligibel, MD reviews a telephone-based weight loss intervention that led to significant improvements in metabolic and inflammatory biomarkers associated with cancer recurrence according to new data.
News
Why Zip Code Matters: How Environment Shapes Cancer Risk
Zip codes didn’t exist until 1963 and were established to help speed the delivery of mail. Today, we rely much less on paper mail but strangely, zip codes play a bigger role.
News
Dana-Farber Research News 12.15.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 16 through November 30.
Document
Capivasertib Plus Fulvestrant for Advanced Estrogen Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of capivasertib plus fulvestrant in patients with advanced estrogen receptor-positive breast cancer.
News
A Vision for Health Equity in Childhood Cancer
The Dana-Farber lab of Kira Bona, MD, MPH, has uncovered an alarming reality: children from low-income households are more likely to experience cancer relapse and face lower survival rates compared to their more privileged peers, despite receiving treatment on highly standardized clinical trials at top academic centers.
News
Early Detection and Interception Research Shows Promise at ASH
Dana-Farber Cancer Institute investigators are leading three separate studies with encouraging results related to the early detection and interception of multiple myeloma.
News
Dana-Farber Research News 12.01.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 1 through November 15.
Symposium
2024 SABCS Highlights
Dana-Farber Cancer Institute Faculty highlights from the 2024 San Antonio Breast Cancer Symposium.
Symposium
2024 ASH Highlights
Review presentations and information shared by Dana-Farber physician-scientists at the 67th American Society of Hematology Annual Meeting & Exposition in San Diego on Dec. 1-10th, 2024.
News
Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers
Dana-Farber Cancer Institute is proud to announce that 42 of its researchers have been named to the Highly Cited Researchers list of 2024, released today by the Institute for Scientific Information at Clarivate.
News
First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber
Investigators at Dana-Farber Cancer Institute are opening a new clinical trial to evaluate a novel type of immune cellular therapy in patients with recurrent, platinum resistant ovarian cancer.